Browse > Article
http://dx.doi.org/10.5941/MYCO.2014.42.3.215

Toxicological Profiles of Poisonous, Edible, and Medicinal Mushrooms  

Jo, Woo-Sik (Department of Agricultural Environment, Gyeongbuk Agricultural Technology Administration)
Hossain, Md. Akil (Laboratory of Clinical Pharmacokinetics and Pharmacodynamics, College of Veterinary Medicine, Kyungpook National University)
Park, Seung-Chun (Laboratory of Clinical Pharmacokinetics and Pharmacodynamics, College of Veterinary Medicine, Kyungpook National University)
Publication Information
Mycobiology / v.42, no.3, 2014 , pp. 215-220 More about this Journal
Abstract
Mushrooms are a recognized component of the human diet, with versatile medicinal properties. Some mushrooms are popular worldwide for their nutritional and therapeutic properties. However, some species are dangerous because they cause toxicity. There are many reports explaining the medicinal and/or toxic effects of these fungal species. Cases of serious human poisoning generally caused by the improper identification of toxic mushroom species are reported every year. Different substances responsible for the fatal signs and symptoms of mushroom toxicity have been identified from various poisonous mushrooms. Toxicity studies of mushroom species have demonstrated that mushroom poisoning can cause adverse effects such as liver failure, bradycardia, chest pain, seizures, gastroenteritis, intestinal fibrosis, renal failure, erythromelalgia, and rhabdomyolysis. Correct categorization and better understanding are essential for the safe and healthy consumption of mushrooms as functional foods as well as for their medicinal use.
Keywords
Mushroom toxicity; Poisonous mushroom; Toxic compounds;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Taguchi T, Tomotoshi K, Mizumura K. Excitatory actions of mushroom poison (acromelic acid) on unmyelinated muscular afferents in the rat. Neurosci Lett 2009;456:69-73.   DOI
2 Musshoff F, Madea B, Beike J. Hallucinogenic mushrooms on the German market: simple instructions for examination and identification. Forensic Sci Int 2000;13:389-95.
3 Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in human via serotonin-2 agonist action. Neuroreport 1998;9:3897-902.   DOI
4 Berger KJ, Guss DA. Mycotoxins revisited: part II. J Emerg Med 2005;28:175-83.   DOI
5 Keller T, Schneider A, Regenscheit P, Dirnhofer R, Rucker T, Jaspers J, Kisser W. Analysis of psilocybin and psilocin in Psilocybe subcubensis Guzman by ion mobility spectrometry and gas chromatography-mass spectrometry. Forensic Sci Int 1999;99:93-105.   DOI
6 Nakanishi K, Ohashi M, Tada M, Yamada Y. Illudins (Lampterol). Tetrahedron 1965;21:1231-46.   DOI
7 Tegzes JH, Puschner B. Toxic mushrooms. Vet Clin North Small Anim Pract 2002;32:397-407.   DOI
8 Warner M, Chen LH, Makuc DM, Anderson RN, Minino AM. Drug poisoning deaths in the United States, 1980-2008 [Internet]. Atlanta: Centers for Disease Control and Prevention; 2011 [cited 2013 Feb 21]. Available from: http://www.cdc.gov/nchs/data/databriefs/db81.htm.
9 Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 2002;60:258-74.   DOI
10 Gao Y, Chan E, Zhou S. Immunomodulating activities of Ganoderma, a mushroom with medicinal properties. Food Rev Int 2004;20:123-61.   DOI
11 Chang R. Functional properties of edible mushrooms. Nutr Rev 1996;54(11 Pt 2):S91-3.
12 Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 1999;19:65-96.
13 Reshetnikov SV, Tan KK. Higher basidiomycota as a source of antitumor and immunostimulating polysaccharides (review). Int J Med Mushrooms 2001;3:361-94.
14 Nieminen P, Kirsi M, Mustonen AM. Suspected myotoxicity of edible wild mushrooms. Exp Biol Med (Maywood) 2006; 231:221-8.   DOI
15 Karlson-Stiber C, Persson H. Cytotoxic fungi: an overview. Toxicon 2003;42:339-49.   DOI
16 Flesch F, Saviuc P. Intoxications par les champignons: principaux syndromes et traitement. EMC Med 2004;1:70-9.
17 White J, Warrell D, Eddleston M, Currie BJ, Whyte IM, Isbister GK. Clinical toxinology: where are we now? J Toxicol Clin Toxicol 2003;41:263-76.   DOI
18 Lin YM, Wang TL. Mushroom poisoning. Ann Disaster Med 2004;3(Suppl 1):S8-11.
19 Wong JH, Ng TB. Toxins from Basiodiomycete fungi (mushrooms): amatoxins, phallotoxins and virotoxins. In: Kastin AJ, editor. Handbook of biologically active peptides. San Diego: Elsevier; 2006. p. 131-5.
20 Tsujikawa K, Mohri H, Kuwayama K, Miyaguchi H, Iwata Y, Gohda A, Fukushima S, Inoue H, Kishi T. Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan. Forensic Sci Int 2006;164:172-8.   DOI
21 Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology and ethnomycology. Mycol Res 2003;107:131-46.   DOI
22 Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata Y, Inoue H, Yoshida T, Kishi T. Determination of muscimol and ibotenic acid in Amanita mushrooms by high-performance liquid chromatography and liquid-chromatography-tandem mass spectrometry. J Chromatogr B Analyt Techonol Biomed Life Sci 2007;852:430-5.   DOI
23 Stormer FC, Koller GE, Janak K. Ibotenic acid in Amanita muscaria spores and caps. Mycologist 2004;18:114-7.   DOI
24 Wieland T, Gotzendorfer C, Zanotti G, Vaisius AC. The effect of the chemical nature of the side chains of amatoxins in the inhibition of eukaryotic RNA polymerase B. Eur J Biochem 1981;117:161-4.
25 Satora L, Pach D, Ciszowski K, Winnik L. Panther cap Amanita pantherina poisoning case report and review. Toxicon 2006;47:605-7.   DOI
26 Rumack BH, Spoerke DG. Handbook of mushroom poisoning: diagnosis and treatment. Boca Raton: CRC Press; 1994. p. 330.
27 Goldfrank LR. Mushrooms. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE editors. Goldfrank's toxicologic emergencies. 9th ed. New York: McGraw-Hill; 2011. p. 1522.
28 Brent J, Palmer RB. Mushrooms. In: Shannon MW, Borron SW, Burns MJ editors. Haddad and Winchester's clinical management of poisoning and drug overdose. 4th ed. Philadelphia: Saunders Elsevier; 2007. p. 455-72.
29 Curtis DR, Lodge D, McLennan H. The excitation and depression of spinal neurones by ibotenic acid. J Physiol 1979;291:19-28.   DOI
30 Ennecker-Jans AS, Van Daele PL, Blonk MI, Varin DS, Van Laar JA. Amatoxin poisoning due to soup from personally picked deathcap mushrooms (Amanita phalloides). Ned Tijdschr Geneeskd 2007;151:764-8.
31 Aygul N, Duzenli MA, Ozdemir K, Altunkeser BB. A case report of unusual complication of Amanita phalloides poisoning: development of cardiogenic shock and its successful treatment with intra-aortic balloon counterpulsation. Toxicon 2010;55: 630-2.   DOI
32 Mount P, Harris G, Sinclair R, Finlay M, Becker GJ. Acute renal failure following ingestion of wild mushrooms. Int Med J 2002;32:187-90.   DOI
33 Zuzek MC, Macek P, Sepci K, Cestnik V, Frangez R. Toxic and lethal effects of ostreolysin, a cytolytic protein from edible oyster mushroom (Pleurotus ostreatus), in rodents. Toxicon 2006;48:264-71.   DOI
34 Bedry R, Baudrimont I, Deffieux G, Creppy EE, Pomies JP, Ragnaud JM, Dupon M, Neau D, Gabinski C, De Witte S, et al. Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med 2001;345:798-802.   DOI
35 Saviuc PF, Danel VC, Moreau PA, Claustre AM, Ducluzeau R, Carpentier PH. Acute erythermalgia: look for mushroons. Rev Med Interne 2002;23:394-9.   DOI
36 Dehay MH, de Sainte Mareville F, Assez N, Dherbecourt V, Goldstein P. Syndrome muscarinique par ingestion de champignon: a propos de deux cas dont un mortel. Eur J Emerg 2009;22:18-23.
37 Berne S, Sepci K, Anderluh G, Turk T, Macek P, Poklar Ulrih N. Effect of pH on the pore forming activity and conformational stability of ostreolysin, a lipid raft-binding protein from the edible mushroom Pleurotus ostreatus. Biochemistry 2005;44:11137-47.   DOI
38 Bedry R, Saviuc P. Severe mushroom poisoning excluding Amanita phalloides syndrome. Reanimation 2002;11:524-32.   DOI
39 Kobayashi N, Endo S, Kobayashi H, Faulstich H, Wieland T, Munekata E. Comparative study on the formation of phalloidin, viroisin and related derivatives in aqueous solution. Eur J Biochem 1995;232:726-36.   DOI
40 Walton K, Coombs MM, Walker R, Ioannides C. The metabolism and bioactivation of agaritine and of other mushroom hydrazines by whole mushroom homogenate and by mushroom tyrosinase. Toxicology 2001;161:165-77.   DOI
41 Kondo K, Watanabe A, Akiyama H, Maitani T. The metabolisms of agaritine, a mushroom hydrazine in mice. Food Chem Toxicol 2008;46:854-62.   DOI
42 Nilsson UA, Nystrom J, Buvall L, Ebefors K, Bjornson-Granqvist A, Holmdahl J, Haraldsson B. The fungal nephrotoxin orellanine simultaneously increases oxidative stress and downregulates cellular defenses. Free Radic Biol Med 2008;44:1562-9.   DOI
43 Arshadi M, Nilsson C, Magnusson B. Gas chromatographymass spectrometry determination of the pentafluorobenzoyl derivative of methylhydrazine in false morel (Gyromitra esculenta) as a monitor for the content of the toxin gyromitrin. J Chromatogr A 2006;1125:229-33.   DOI